{"analyses":[{"ciLowerLimit":"0.465","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.850","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0024","pValueComment":"P value is from stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.629","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.8","upperLimit":"54.5","value":"31.9"},{"groupId":"OG001","lowerLimit":"16.5","upperLimit":"29.5","value":"22.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of randomization to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg) for approximately 104 weeks, followed by ibrutinib monotherapy until PD, unacceptable toxicity or withdrawal of consent. Venetoclax was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG000","title":"Randomization Phase: Ibrutinb + Venetoclax"},{"description":"Participants were randomized to ibrutinib 560 mg and placebo for approximately 104 weeks, followed by ibrutinib monotherapy until PD, unacceptable toxicity or withdrawal of consent. Placebo was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG001","title":"Randomization Phase: Ibrutinib + Placebo"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 61.34 months","title":"Progression-free Survival (PFS) (Randomization Phase)","type":"PRIMARY","unitOfMeasure":"months"}